Navigation Links
Groundbreaking MS research to be presented at American Academy of Neurology Annual Meeting
Date:4/13/2010

Researchers from Mount Sinai School of Medicine will present several studies at the American Academy of Neurology (AAN) Annual Meeting, including a potential new drug for the treatment of multiple sclerosis (MS) and surprising trends showing a reduction in the disease's severity. The meeting will take place April 10-17 in Toronto.

  • "Oral Teriflunomide or Placebo Added to Glatiramer Acetate for 6 Months in Patients with Relapsing Multiple Sclerosis: Safety and Efficacy Results"
    (To be presented Wednesday, April 14, 2010 at 2:00 PM EDT.)

Mount Sinai researchers took part in a Phase II study of teriflunomide, an investigational oral medication for relapsing-remitting multiple sclerosis (RRMS), the most common form of the disease. The study analyzed teriflunomide added to ongoing treatment with glatiramer acetate, a currently prescribed medication, and determined that teriflunomide was safe and effective as part of combination therapy.

Researchers evaluated 123 patients with RRMS over 24 weeks. Patients were given teriflunomide in doses of seven mg/day or 14 mg/day, while a control group received a placebo. Study participants were evaluated through physical examination, laboratory data, electrocardiogram, pancreatic ultrasound, and MRI.

Teriflunomide had a positive safety profile, with only seven treatment emergent adverse events (TEAE) leading to treatment discontinuation. MRI studies revealed that teriflunomide also proved to be effective at reducing the size and volume of lesions on the brain.

"While our study was designed to evaluate the safety of teriflunomide, we determined that in addition to being safe it was also effective in reducing the size and number of lesions in people with RRMS," said Aaron Miller, MD, Professor of Neurology, and Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine. "Further data are required to evaluate efficac
'/>"/>

Contact: Mount Sinai Press Office
newsnow@mountsinai.org
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Groundbreaking research shows platelets can reproduce in circulation
2. Statement by Blue Shield of California CEO Bruce Bodaken Regarding the Groundbreaking for the Family Violence Prevention Funds International Center
3. Groundbreaking Principal and Contributor on Dr. Oz Show Releases His Latest Book on How We Can Influence the Lives of Children
4. Texas-based consortium announces groundbreaking vaccine research program
5. $250,000 grant awarded for groundbreaking ligament and tendon repair research
6. $250,000 Grant Awarded for Groundbreaking Ligament and Tendon Repair Research
7. Groundbreaking Study Using Ultrasound for the Treatment of Intracerebral and Intraventricular Hemorrhage Stroke Shows Promise
8. Groundbreaking research to find vaccine for hepatitis C
9. LASIK Surgeons, Plastic Surgeons, Cosmetic Dentists and other Cash Paid Medical Specialists Brought Together for Groundbreaking Webinar Series
10. New research identifies modifiable risk factors for heart disease
11. Nuvo Research announces early redemption of 5% convertible debentures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 My Clients Plus ( http://www.MyClientsPlus.com ... The new module enables easy administration and routing ... quality care. , This application allows users such as ... attach a to-do item to a specific client, categorize ... up reoccurring reminders for follow-ups. It's designed to ...
(Date:10/20/2014)... AttorneyOne.com, a recognized authority on law, update ... FDA on Sit and Slim II . , ... or use Sit and Slim II because it contains ... as weight loss product on various websites and possibly in ... 2010 for safety reasons, can significantly increase blood pressure and/or ...
(Date:10/20/2014)... OH (PRWEB) October 20, 2014 ... Assisted Living Center on Oct. 14. The $11 million ... and services, and a cooked-to-order kitchen with full-service restaurant ... Akron’s premier choice for first class Assisted Living apartments,” ... “Our residents deserve the highest quality of care and ...
(Date:10/20/2014)... 20, 2014 Based on a ... only imaging assays capable of determining DNA sequence, ... With these three dimensions of high-resolution data, dGH ... the widest range of disease-causing genetic rearrangements, including ... other genomic tools, including today’s advanced sequencing technologies. ...
(Date:10/20/2014)... California (PRWEB) October 20, 2014 Final Cut ... the release of the Citrus theme for FCPX filmmakers ... would use to describe the Citrus theme” Says Christina Austin, ... easy to look so professional.” , Citrus comes with all ... with the template are: four transitions for added style, a ...
Breaking Medicine News(10 mins):Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2
... , CHARLOTTE, N.C., July 17 ... an affiliate of US HIFU -- a worldwide leader in ... focused ultrasound (HIFU) technologies -- officially launches Sonablate((R)) HIFU services ... Gandhi Cancer Institute & Research Centre (RGCI & RC) on ...
... Gene, brain activity may determine child,s temperament, study finds , ... easy baby or a fussy one may have nothing to ... certain gene and a particular pattern of brain activity may ... Canadian researchers examined the interaction between the DRD4 gene and ...
... remain volatile issues in the drive for bipartisan support , ... to overhaul the nation,s health-care system started to emerge from ... that this may, at long last, be the year that ... health care more affordable. , "I think we,re in a ...
... , DOYLESTOWN, Pa., July 17 The ... www.quigleyco.com , today announced that Ted Karkus, ... Executive Officer by the Board of Directors of the Company. The ... Chief Operating Officer. , , ...
... July 17 Masimo Corporation (Nasdaq: MASI ), ... pending litigation under which Masimo and Respironics will dismiss all claims and ... As part of the settlement, Respironics and Masimo have agreed upon ... , About Masimo , ...
... TSX: BMR , , TORONTO, July 17 /PRNewswire-FirstCall/ ... "Corporation") announced today that its Board of Directors has ... bid (the "Offer"), pursuant to which the Corporation will ... of its outstanding common shares ("Shares") at a price ...
Cached Medicine News:Health News:Innovative Prostate Cancer Treatment Known as Sonablate(R) HIFU Now Available at Third Site in India 2Health News:Easy Baby or Fussy -- It May Be Out of Mom's Control 2Health News:Congress Braces for Showdown Over Health-Care Reform 2Health News:Congress Braces for Showdown Over Health-Care Reform 3Health News:Ted Karkus Named CEO of The Quigley Corporation; Robert V. Cuddihy, Jr. Named Chief Operating Officer 2Health News:Ted Karkus Named CEO of The Quigley Corporation; Robert V. Cuddihy, Jr. Named Chief Operating Officer 3Health News:Ted Karkus Named CEO of The Quigley Corporation; Robert V. Cuddihy, Jr. Named Chief Operating Officer 4Health News:Masimo Announces Settlement of Lawsuit 2Health News:Masimo Announces Settlement of Lawsuit 3Health News:Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid 2Health News:Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid 3Health News:Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid 4
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014   BioNano ... the Irys system: the ability to collect human data at ... on a single chip.  This new capability was established and ... for the Irys TM System and will ... next two months. BioNano will be showcasing this advancement at ...
(Date:10/20/2014)... , Oct. 20, 2014 Pharmaceutic Labs announces ... in Albany, NY for admixing, ... company meets and/or exceeds the FDA standards for safety ... CFR Part 211. The 10,000 square ... levels of quality assurance and quality control. The company ...
(Date:10/19/2014)... , October 20, 2014 Shire plc ... Bowling , Interim Chief Financial Officer (CFO), has notified the Board ... role to pursue a new career opportunity as CFO of Severn ... 2015 and the company will commence a search for a new ... "James has helped build and lead a high-quality finance ...
Breaking Medicine Technology:BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Interim Chief Financial Officer James Bowling to Step Down 2Interim Chief Financial Officer James Bowling to Step Down 3Interim Chief Financial Officer James Bowling to Step Down 4
... Ill., Nov. 8, 2010 ... ... --> ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... 8, 2010 Reportlinker.com announces that a ... its catalogue: The Future ... leading companies, and opportunities for target expansion ... G-Protein-coupled receptors (GPCRs) constitute the largest ...
Cached Medicine Technology:Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 2Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 3Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 4Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 5Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 6Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 7Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 8The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 2The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 3The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 4The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 5